Turn Therapeutics Inc (TTRX)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks...

Form 8-K - Current report

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

Study demonstrates statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression First...

Form 8-K - Current report

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin...

Form 8-K - Current report

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

Dr. Hahn Brings Unparalleled Clinical and Regulatory Expertise to Support Advancement of GX-03 for Moderate-to-Severe Atopic Dermatitis and...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Phase 2 Trial for GX-03 in Moderate-to-Severe Atopic Dermatitis (AD) on Track, Topline Results Expected Mid-2026 Initial Tranche of $7 Million in...